APA (7th ed.) Citation

Lin, H., Li, B., & Rong, D. Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): A cost-effectiveness analysis in the USA. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Lin, Hui, Biao Li, and Dingchao Rong. Atezolizumab Monotherapy as First-line Treatment for Non-small Cell Lung Cancer Ineligible for Treatment with a Platinum-containing Regimen (IPSOS): A Cost-effectiveness Analysis in the USA. BMJ Publishing Group.

MLA (9th ed.) Citation

Lin, Hui, et al. Atezolizumab Monotherapy as First-line Treatment for Non-small Cell Lung Cancer Ineligible for Treatment with a Platinum-containing Regimen (IPSOS): A Cost-effectiveness Analysis in the USA. BMJ Publishing Group.